108139
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
年龄相关脆性 X 综合征（FXS）患儿血清代谢及肠道微生物组差异可能有助于临床治疗的发展
Authors Han X, Zhu J, Zhao W, Han Y
Received 19 June 2025
Accepted for publication 6 September 2025
Published 26 September 2025 Volume 2025:18 Pages 5869—5882
DOI https://doi.org/10.2147/IJGM.S548349
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Gopal Krishna Dhali
Xiaqing Han,* Jianen Zhu,* Wenying Zhao, Ying Han
Department of Pediatrics, Peking University First Hospital, Xicheng District, Beijing, 100034, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Ying Han, Department of Pediatrics, Peking University First Hospital, Xicheng District, No. 8 Xishiku Street, Xicheng District, Beijing, 100034, People’s Republic of China, Tel +86013661013288, Email hanying1568@bjmu.edu.cn
Background: Fragile X syndrome (FXS) is a rare, genetically based neurodevelopmental disorder characterized by intellectual disability. While previous research has largely focused on its genetic mechanisms, the role of metabolism and the gut microbiome in FXS remains underexplored. This study aimed to investigate age-related metabolic differences in the gut flora and serum metabolites of children with FXS and their associations with clinical behavioral outcomes.
Methods: A total of 32 children with FXS under 18 years were enrolled and divided into two age groups: younger (3– 8 years) and older (8– 18 years). Intestinal microbiota composition was analyzed using 16S rDNA gene sequencing, and serum metabolite profiles were assessed via ultra-performance liquid chromatography-mass spectrometry (UPLC-MS). Spearman correlation analysis was used to assess associations among gut flora, serum metabolites, and scores from the Social Responsiveness Scale (SRS) and Child Behavior Checklist (CBCL).
Results: Significant differences in gut bacterial genera and 1,352 serum metabolites were observed between the age groups. The older group exhibited higher levels of phospholipids, steroids, and peptides, and enrichment in the steroid hormone biosynthesis pathway. Several metabolites were significantly correlated with SRS and CBCL scores, indicating potential links between metabolic changes and behavioral symptoms.
Conclusion: Age-associated metabolic and gut microbiota alterations in FXS may contribute to variations in clinical presentation. These findings suggest a metabolic basis for FXS and provide a foundation for future research into microbiome-targeted interventions in FXS management.
Keywords: fragile X syndrome, gut microbiome, metabolites
Department of Pediatrics, Peking University First Hospital, Xicheng District, Beijing, 100034, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Ying Han, Department of Pediatrics, Peking University First Hospital, Xicheng District, No. 8 Xishiku Street, Xicheng District, Beijing, 100034, People’s Republic of China, Tel +86013661013288, Email hanying1568@bjmu.edu.cn
Background: Fragile X syndrome (FXS) is a rare, genetically based neurodevelopmental disorder characterized by intellectual disability. While previous research has largely focused on its genetic mechanisms, the role of metabolism and the gut microbiome in FXS remains underexplored. This study aimed to investigate age-related metabolic differences in the gut flora and serum metabolites of children with FXS and their associations with clinical behavioral outcomes.
Methods: A total of 32 children with FXS under 18 years were enrolled and divided into two age groups: younger (3– 8 years) and older (8– 18 years). Intestinal microbiota composition was analyzed using 16S rDNA gene sequencing, and serum metabolite profiles were assessed via ultra-performance liquid chromatography-mass spectrometry (UPLC-MS). Spearman correlation analysis was used to assess associations among gut flora, serum metabolites, and scores from the Social Responsiveness Scale (SRS) and Child Behavior Checklist (CBCL).
Results: Significant differences in gut bacterial genera and 1,352 serum metabolites were observed between the age groups. The older group exhibited higher levels of phospholipids, steroids, and peptides, and enrichment in the steroid hormone biosynthesis pathway. Several metabolites were significantly correlated with SRS and CBCL scores, indicating potential links between metabolic changes and behavioral symptoms.
Conclusion: Age-associated metabolic and gut microbiota alterations in FXS may contribute to variations in clinical presentation. These findings suggest a metabolic basis for FXS and provide a foundation for future research into microbiome-targeted interventions in FXS management.
Keywords: fragile X syndrome, gut microbiome, metabolites